Cellaviva delivers stem cells to treat serious blood disease

April 1, 2022

Cordblood contains blood stem cells and is routinely used to treat severe diseasesof the blood and immune system. The treatment is similar to bone marrow stem celltherapy and the most common use of cord blood is sibling donation for thetreatment of childhood leukaemia.

NextCellowns the Cellaviva biobank, which has been helping pregnant parents savestem cells in connection with childbirth since 2015. The umbilical cord bloodthat is saved is the blood that remains in the placenta and umbilical cordafter the baby is born and the cord has been cut. In addition, a piece of theumbilical cord is also collected to grow connective tissue-forming stem cells.Haematopoietic stem cells can mature into all types of blood cells and immunecells, while connective tissue stem cells can mature into other tissues such ascartilage, fat and bone.

“ Thepurpose of preserving stem cells is not the saving itself, but to have rapidaccess to the highest quality stem cells in case of serious disease. Ourorganisation contributes to the development of new therapies and the expansionof treatment options for affected patients. Ultimately, it's about savinglives," says Mathias Svahn, vd NextCell.

Thecollection of stem cells from the umbilical cord does not alter the birthingprocess in any way and is risk-free. Currently, there are over 80 healthconditions with cord blood stem cells as an approved treatment option. In addition,experimental treatments using cord blood and cord tissue stem cells are beingevaluated for conditions such as cerebral palsy and type 1 diabetes. NextCellis conducting its own clinical trials with cells from donated umbilical cordsfor the treatment of type 1 diabetes and severe pneumonia caused by COVID-19.

For more information aboutCellaviva, please contact:

SofieFalk-Jansson, Commercial Director

Tel: 08-735 2010

E-mail: info@cellaviva.se

Webpage: www.cellaviva.se | www.cellaviva.dk

Instagram: https://www.instagram.com/cellaviva/

Facebook: https://www.facebook.com/cellavivasverige/

For more information about NextCell PharmaAB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel:08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

About NextCell Pharma AB

NextCell is a phase II cell therapy company withthe drug candidate ProTrans for the treatment of type 1 diabetes. The focus isto take ProTrans to market approval via a Phase III study. ProTrans is inaddition to diabetes, used in two clinical trials for Covid-19, in Örebro andMontreal (Canada). The company is in the processes of establishing its own GMPfacility for production of ProTrans. The GMP facility is expected to be readyfor production of smaller quantities of ProTrans in 2023. NextCell furthermoreowns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva,Scandinavia's largest stem cell bank for family saving stem cells fromumbilical cord blood and umbilical cord tissue with permission from the SwedishHealth and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2023-08-08

ProTrans and NextCell gain international attention

Results from Professor Per-Ola Carlsson, Principal Investigator for NextCell’s Phase-I/II study with ProTrans stromal cells for Type 1 Diabetes are now published and featured in the Up-front section of the current issue of Diabetologia. The article was selected by the Editor as worthy of special attention, for its high quality and interest to the diabetes field. Furthermore, the article has already been cited in an International scientific journal.

Read more Read more

2023-07-27

NextCell publishes its Interim Report 3 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2023 – May 31, 2023 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2023-07-05

Treatment start of severe pneumonia with high dose of ProTrans

NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans 19+SE (also called Protrans V) can start recruiting patients in the high dose group, which is the last dose group. Three patients treated with medium dose of ProTrans have been clinically evaluated and the data has been reviewed by the Data Safety Monitoring Board, which now allows continued treatment with high-dose ProTrans for severe pneumonia caused by COVID-19, Influenza, Human Metapneumovirus and RSV.

Read more Read more

2023-05-30

NextCell invited presenter at International Society for Cell and Gene Therapy meeting in Paris

NextCell Pharma AB's ("NextCell" or the"Company") CSO, Dr Lindsay Davies, has been invited to give a poster presentation at the ISCT meeting in Paris, showcasing NextCell´s long-term follow-up data from their phase II type I diabetes study with investigative medicinal product, ProTrans.

Read more Read more

2023-04-27

NextCell publishes its Interim Report 2 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2022 – February 28, 2023 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2023-04-26

Breakthrough multiplication of blood stem cells

NextCell Pharma AB (“NextCell” or the “company") announces that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia. Cellaviva is a part of NextCell with offices in Stockholm and Copenhagen.

Read more Read more

2023-04-18

NextCell invited speaker at European Wound Management Association Meeting in Milan

NextCell Pharma AB´s ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell´s phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.

Read more Read more

2023-03-28

NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.

Read more Read more